NO970787L - Fremgangsmåte for hemming av primær endometrial hyperplasi - Google Patents

Fremgangsmåte for hemming av primær endometrial hyperplasi

Info

Publication number
NO970787L
NO970787L NO970787A NO970787A NO970787L NO 970787 L NO970787 L NO 970787L NO 970787 A NO970787 A NO 970787A NO 970787 A NO970787 A NO 970787A NO 970787 L NO970787 L NO 970787L
Authority
NO
Norway
Prior art keywords
endometrial hyperplasia
inhibition
procedure
primary endometrial
primary
Prior art date
Application number
NO970787A
Other languages
English (en)
Norwegian (no)
Other versions
NO970787D0 (no
Inventor
Robin Sharon Lee Fuchs-Young
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO970787D0 publication Critical patent/NO970787D0/no
Publication of NO970787L publication Critical patent/NO970787L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
NO970787A 1994-08-22 1997-02-20 Fremgangsmåte for hemming av primær endometrial hyperplasi NO970787L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29412194A 1994-08-22 1994-08-22
PCT/US1995/010619 WO1996005832A1 (en) 1994-08-22 1995-08-21 Methods of inhibiting primary endometrial hyperplasia

Publications (2)

Publication Number Publication Date
NO970787D0 NO970787D0 (no) 1997-02-20
NO970787L true NO970787L (no) 1997-02-20

Family

ID=23131973

Family Applications (1)

Application Number Title Priority Date Filing Date
NO970787A NO970787L (no) 1994-08-22 1997-02-20 Fremgangsmåte for hemming av primær endometrial hyperplasi

Country Status (20)

Country Link
EP (1) EP0771201B1 (cs)
JP (1) JPH10504579A (cs)
KR (1) KR970705388A (cs)
AT (1) ATE200623T1 (cs)
AU (1) AU706953B2 (cs)
CA (1) CA2198120A1 (cs)
CZ (1) CZ52297A3 (cs)
DE (1) DE69520741T2 (cs)
DK (1) DK0771201T3 (cs)
ES (1) ES2155895T3 (cs)
FI (1) FI970716L (cs)
GR (1) GR3036225T3 (cs)
HU (1) HUT76854A (cs)
IL (1) IL115018A0 (cs)
MX (1) MX9701359A (cs)
MY (1) MY131931A (cs)
NO (1) NO970787L (cs)
PT (1) PT771201E (cs)
WO (1) WO1996005832A1 (cs)
ZA (1) ZA956988B (cs)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU688112B2 (en) * 1994-08-22 1998-03-05 Eli Lilly And Company Methods of inhibiting endometrial cancer
US5843964A (en) * 1994-09-22 1998-12-01 Eli Lilly And Company Methods of inhibiting endometrial mitoses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
CZ253694A3 (en) * 1993-10-15 1995-05-17 Lilly Co Eli Pharmaceutical preparation for treating resistant neoplasms
US5461065A (en) * 1993-10-15 1995-10-24 Eli Lilly And Company Methods for inhibiting endometriosis

Also Published As

Publication number Publication date
CA2198120A1 (en) 1996-02-29
EP0771201A4 (en) 1997-09-10
EP0771201A1 (en) 1997-05-07
DK0771201T3 (da) 2001-05-07
KR970705388A (ko) 1997-10-09
EP0771201B1 (en) 2001-04-18
JPH10504579A (ja) 1998-05-06
FI970716A7 (fi) 1997-02-20
WO1996005832A1 (en) 1996-02-29
ATE200623T1 (de) 2001-05-15
MX9701359A (es) 1997-05-31
ZA956988B (en) 1997-02-21
ES2155895T3 (es) 2001-06-01
DE69520741T2 (de) 2001-10-11
IL115018A0 (en) 1995-12-08
NO970787D0 (no) 1997-02-20
HUT76854A (en) 1997-12-29
DE69520741D1 (de) 2001-05-23
AU3409895A (en) 1996-03-14
AU706953B2 (en) 1999-07-01
CZ52297A3 (en) 1997-08-13
MY131931A (en) 2007-09-28
FI970716A0 (fi) 1997-02-20
GR3036225T3 (en) 2001-10-31
PT771201E (pt) 2001-07-31
FI970716L (fi) 1997-02-20

Similar Documents

Publication Publication Date Title
NO971520L (no) Fremgangsmåte for hemming av tilstander forbundet med neuropeptid Y
UA26930C2 (uk) Засіб для іhгібуваhhя еhдометріозу
DK0651999T3 (da) Fremgangsmåder til inhibering af livmoderfibrose
MX9701329A (es) Metodos para la inhibicion de la replicacion viral.
DK0659416T3 (da) Inhibering af seborE og acne
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
NO944933L (no) Fremgangsmåte for å inhibere sykdomstilstander i brystet
NO944917D0 (no) Anvendelse av 2-fenyl-3-aroyltiofener for inhibering av eggstokkdysgenese, forsinket pubertet eller seksuell infantilisme
NO970786L (no) Fremgangsmåte for hemming av benprotesedegradering
NO975580L (no) Fremgangsmåte for å inhibere melanom
NO981578L (no) FremgangsmÕte for hemming av plasminogenaktivatorhemmer I
NO973609L (no) Fremgangsmåte for å inhibere effektene av IL-6
NO971794L (no) Fremgangsmåte for hemming av tilstander forbundet med bradykinin
NO944920L (no) Fremgangsmåte for å inhibere hirsutisme og alopecia hos kvinner
MX9701333A (es) Metodos para inhibir el daño neuronal.
NO970783L (no) Fremgangsmåte for å hindre endometrialkreft
NO971029L (no) Fremgangsmåter for hemming av endometriale metoser
NO970787D0 (no) Fremgangsmåte for hemming av primær endometrial hyperplasi
NO973103L (no) Fremgangsmåte for inhibering av veksthormoneffekter
NO944909L (no) Fremgangsmåter for inhibering av mannlig infertilitet
NO973470L (no) Fremgangsmåte for minsking av serumkalsiumnivåer